Showing 881 - 900 results of 47,792 for search '(( a ((((teer decrease) OR (mean decrease))) OR (linear decrease)) ) OR ( a largest decrease ))', query time: 0.93s Refine Results
  1. 881
  2. 882

    Participants’ Mean Blood Glucose. by Giti Azim (20940548)

    Published 2025
    “…Total cholesterol and blood glucose were the outcome variables for this study; simple and multiple linear regression was performed to find the associated factors for the outcome variables using a designed-based modeling incorporating sampling techniques and weights. …”
  3. 883

    Participants’ Mean Total Cholesterol. by Giti Azim (20940548)

    Published 2025
    “…Total cholesterol and blood glucose were the outcome variables for this study; simple and multiple linear regression was performed to find the associated factors for the outcome variables using a designed-based modeling incorporating sampling techniques and weights. …”
  4. 884
  5. 885
  6. 886
  7. 887
  8. 888
  9. 889
  10. 890
  11. 891

    Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…One hundred percent cell viability corresponds to the number of living cells incubated with transfecting agent only. Results are the mean ± SD of two independent experiments containing 8 replicates for each condition. * = <i>p</i><0.05, ** = <i>p</i><0.01, *** = <i>p</i><0.001, significant decrease compared to untreated cells (TA) or to siRNA Control (Kruskal & Wallis followed by Tukey and Dunnet test).…”
  12. 892

    List of Included studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  13. 893

    The search strategy in three databases. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  14. 894

    NIH score. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  15. 895

    List of excluded studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  16. 896
  17. 897
  18. 898
  19. 899

    Effects of siRNA TMPRSS2-ERG on ERG protein expression and cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…<p>VCaP cells were transfected for 24h, 48h and 72h with 50 nM of siRNAs TMPRSS2-ERG III (1, 2, 3), siRNAs TMPRSS2-ERG IV (1, 2), siRNA against ERG wild type or siRNA Control. <b>a. Western blot analysis:</b> the expression of ERG protein detected by Western blot showed the effects of siRNAs against TMPRSS2-ERG, ERG wild type or siRNA Control. …”
  20. 900